A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non-Small-Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Wang, Siying ^a,b   Peng, Liubao ^a   Li, Jianhe ^a,b   Zeng, Xiaohui ^a,b   Ouyang, Lihui ^a,b   Tan, Chongqing ^a,b   Lu, Qiong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHINA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PROBABILITY; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COSTS AND COST ANALYSIS; DEOXYCYTIDINE; FAR EAST; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MODELS, ECONOMIC; QUINAZOLINES; TIME FACTORS;

EID: 84874764809     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055917     Document Type: Article

References (56)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Chen YM, Peng JW, Chen CM, (2011) First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer-A Review. J Exp Clin Med 3: 116-120.
3. Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, et al. (2011) Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous nonsmall cell lung cancer. J Thorac Oncol 6: 64-70.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92e8.
5. Goffin J, Lacchetti C, Ellis PM, Yee C, Evans WK, et al. (2010) First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 5: 260-274.
6. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
7. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, et al. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT. J Clin Oncol 22: 777-784.
8. Herbst RS, Giaccone G, Schiller JH, Natale RB, Vincent M, et al. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22: 785-794.
9. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, et al. (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25: 1545-1552.
10. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, et al. (2005) TRIBUTE:a phase III trial of erlotinib hydrochloride (OSI-774)combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892-5899.
11. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-57.
12. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967.
13. Zhu CQ, Santos GC, Ding K, Sakurada A, Cutz JC, et al. (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26: 4268-75.
14. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 11: 121-28.
15. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-88.
16. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, et al. (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521-29.
17. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-67.
18. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-46.
19. Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, et al. (2007) Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centres in mainland China. J Thorac Oncol 2: 430-39.
20. Paz-Ares L, Sanchez JM, García-Velasco A, Massuti B, López-Vivanco G, et al. (2006) A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 124: 7020.
21. Giaccone G, Lechevalier T, Thatcher N, Smit E, Janmaat M, et al. (2005) phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer. J Clin Oncol 2005; 23 16S: 7073.
22. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246.
23. Zhou C, Wu YL, Chen G, Feng JF, Liu XQ, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742.
24. Wu B, Ye M, Chen HF, Shen JF, (2012) Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context. Clinical Therapeutics 34: 468-479.
25. Wu B, Chen HF, Shen JF, Ye M, (2011) Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China. Clinical Therapeutics 33: 1446-1455.
26. Zeng XH, Karnon J, Wang SY, Wu B, Wan XM, et al. (2012) The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience. PLOS ONE 7: e48323.
27. Peasgood T, Herrmann K, Kanis JA, Brazier JE, (2009) An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 20: 853-868.
28. Doyle S, Lloyd A, Walker M, (2008) Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 62: 374-380.
29. Lewis G, Peake M, Aultman R, Gyldmark M, Morlotti L, et al. (2010) Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res 38: 9-21.
30. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J, (2008) Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 6: 84.
31. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL, (2009) The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 12: 20-27.
32. China Center for Health Economic Research. China Guidelines for Pharmacoeconomic Evaluations (Version 8). Available: http://www1.gsm.pku.edu.cn/article/143/8010.html. Accessed 2012 Aug 1.
33. Murray CJ, Evans DB, Acharya A, Baltussen RM, (2000) Development of WHO guidelines on generalized costeffectiveness analysis. Health Econ 9: 235-251.
34. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B, (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7: 518-528.
35. Carlson JJ, (2009) Erlotinib in Non-small-cell lung cancer: a review of the clinical and economic evidence. Pharmacoeconomics Outcomes Res 9: 409-416.
36. Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, et al. (2012) Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. ClinicoEconomics and Outcomes Research 4: 269-275.
37. Fragoulakis VF, Pallis AG, Kaitelidou DK, Maniadakis NM, Georgoulias VG, (2012) Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis. Lung Cancer: Targets and Therapy 3: 43-51.
38. Cromwell I, Kimberly VDH, Taylor SC, Barbara M, Stuart P, (2012) Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis. Lung Cancer 76: 472-477.
39. Cromwell I, Kimberly VDH, Barbara M, Stuart P, (2011) Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis. Journal of Thoracic Oncology 6: 2097-2103.
40. Williamson L, Katherine A, (2010) Erlotinib: A Pharmacoeconomic Review of its Use in Advanced Non-Small Cell Lung Cancer. Pharmacoeconomics 28: 75-92.
41. Bradbury PA, Tu DS, Seymour L, Isogai PK, Zhu L, et al. (2010) Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer. J Natl Cancer Inst 102: 298-306.
42. Stephen DS, Mario GS, Eduardo AV, (2008) Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective. Journal of Medical Economics 11: 383-39.
43. Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, et al. (2008) Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 61: 405-415.
44. Alain V, Joshua AR, Christos C, Francesco G, Helge GB, et al. (2012) Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. ClinicoEconomics and Outcomes Research 4: 31-37.
45. Schiller J, Tilden D, Aristides M, Lees M, Kielhorn A, et al. (2004) Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung cancer 43: 101-112.
46. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
47. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
48. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, et al. (2005) Epidermal growth factor r eceptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829-6837.
49. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, et al. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520.
50. Chan SK, Gullick WJ, Hill ME, (2006) Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J Cancer 42: 17-23.
51. Chouaid C, Caer HL, Corre R, Jacquy Crequit, Chrystelle Locher, et al. (2012) Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non-small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 Study (GFPC 0505). Available from: Clinical Lung Cancer: http://dx.doi.org/10.1016/j.cllc.2012.04.006.
52. Chouaid C, Caer HL, Locher C, Dujon C, Thomas P, et al. (2012) Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504). BMC Cancer 12: 301.
53. Bongers ML, Coupe MH, Jansma EP, Jansma EP, Smit EF, et al. (2012) Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer. Pharmacoeconomics 30: 17-34.
54. Borget I, Cadranel J, Pignon J-P, Quoix E, Coudert B, et al. (2012) Cost-effectiveness of three strategies for second-line erlotinib initiation in non smallcell lung cancer: the ERMETIC study part 3. Eur Respir J 39: 172-179.
55. Sequist LV, Pawel JV, Garmey EG, Akerley WL, Brugger W, et al. (2011) Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 29: 3307-3315.
56. Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoil V, et al. (2011) Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models. Cancer Prev Res 4: 818.